Background & AimsTo clarify the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). MethodsThe participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as estimated glomerular … Continue reading Metabolic associated fatty #liver disease is the risk factor for chronic #kidney disease
Tag: fatty-liver
Tamoxifen (TAM) and Toremifene (TOR), two kinds of selective estrogen receptor modulators (SERMs), have equal efficacy in breast cancer patients. However, TAM has been proved to affect serum lipid profiles and cause fatty liver disease. The study aimed to compare the effects of TAM and TOR on fatty liver development and lipid profiles. MethodsThis study … Continue reading Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
Non-alcoholic fatty liver disease (NAFLD) increases morbidity and mortality. However, patients in biopsy-based cohorts are highly selected and the absolute risks of liver- and non-liver outcomes in NAFLD in population remains undefined. We analyzed both liver-related and non-liver-related outcomes in Finnish population cohorts of NAFLD. MethodsWe included 10993 individuals (6707 men, mean age 53.3±12.6 years) … Continue reading Incidence of #liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease
Patients with nonalcoholic fatty liver disease (NAFLD) are characterized by insulin resistance and hyperinsulinism. However, insulin resistance measurements have not been shown to be good diagnostic tools to predict NAFLD in prior studies. ObjectiveWe aimed to assess a newly validated method to measure intact molecules of insulin by mass spectrometry to predict NAFLD. MethodsPatients underwent … Continue reading Intact Fasting #Insulin Identifies Nonalcoholic Fatty #Liver Disease in Patients Without Diabetes
Statin liver safety in non-alcoholic fatty liver disease (NAFLD) patients is not well defined. We analysed differences in liver function tests, including alanine transaminase aminotransferase (ALT), aspartate transaminase (AST), and gamma-glutamyl transpeptidase (GGT) in NAFLD patients treated or not with statins. MethodsWe performed a systematic review of MEDLINE via PubMed and EMBASE databases and metanalysis … Continue reading #Statin liver safety in non-alcoholic fatty #liver disease. A systematic review and metanalysis
2Medical.News 